GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
GO:2001235110 | Esophagus | ESCC | positive regulation of apoptotic signaling pathway | 92/8552 | 126/18723 | 3.91e-10 | 1.05e-08 | 92 |
GO:200124417 | Esophagus | ESCC | positive regulation of intrinsic apoptotic signaling pathway | 43/8552 | 58/18723 | 9.86e-06 | 9.37e-05 | 43 |
GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
GO:200123510 | Oral cavity | OSCC | positive regulation of apoptotic signaling pathway | 92/7305 | 126/18723 | 8.45e-15 | 5.19e-13 | 92 |
GO:20012449 | Oral cavity | OSCC | positive regulation of intrinsic apoptotic signaling pathway | 44/7305 | 58/18723 | 1.22e-08 | 2.48e-07 | 44 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:00487713 | Oral cavity | OSCC | tissue remodeling | 84/7305 | 175/18723 | 9.39e-03 | 3.36e-02 | 84 |
GO:0045453 | Oral cavity | OSCC | bone resorption | 35/7305 | 65/18723 | 1.07e-02 | 3.64e-02 | 35 |
GO:0097193110 | Oral cavity | LP | intrinsic apoptotic signaling pathway | 146/4623 | 288/18723 | 9.76e-22 | 2.78e-19 | 146 |
GO:2001233110 | Oral cavity | LP | regulation of apoptotic signaling pathway | 168/4623 | 356/18723 | 1.35e-20 | 3.02e-18 | 168 |
GO:2001242110 | Oral cavity | LP | regulation of intrinsic apoptotic signaling pathway | 95/4623 | 164/18723 | 9.85e-20 | 1.99e-17 | 95 |
GO:200123518 | Oral cavity | LP | positive regulation of apoptotic signaling pathway | 63/4623 | 126/18723 | 7.17e-10 | 3.43e-08 | 63 |
GO:200124416 | Oral cavity | LP | positive regulation of intrinsic apoptotic signaling pathway | 33/4623 | 58/18723 | 1.63e-07 | 5.11e-06 | 33 |
GO:009719329 | Skin | cSCC | intrinsic apoptotic signaling pathway | 150/4864 | 288/18723 | 1.76e-21 | 3.34e-19 | 150 |
GO:200123329 | Skin | cSCC | regulation of apoptotic signaling pathway | 173/4864 | 356/18723 | 2.25e-20 | 3.44e-18 | 173 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IL20RA | SNV | Missense_Mutation | | c.900N>A | p.Phe300Leu | p.F300L | Q9UHF4 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL20RA | SNV | Missense_Mutation | | c.900N>A | p.Phe300Leu | p.F300L | Q9UHF4 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
IL20RA | SNV | Missense_Mutation | rs774469920 | c.1478N>T | p.Ser493Leu | p.S493L | Q9UHF4 | protein_coding | tolerated(0.06) | possibly_damaging(0.51) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IL20RA | SNV | Missense_Mutation | novel | c.1295N>C | p.Leu432Ser | p.L432S | Q9UHF4 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IL20RA | SNV | Missense_Mutation | novel | c.289C>A | p.Leu97Ile | p.L97I | Q9UHF4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL20RA | insertion | Frame_Shift_Ins | novel | c.1175_1176insTGGCATCAGTTTTCCATCTGCACATATA | p.Pro393GlyfsTer13 | p.P393Gfs*13 | Q9UHF4 | protein_coding | | | TCGA-B5-A11F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
IL20RA | insertion | Frame_Shift_Ins | novel | c.1114_1115insGCAGGCTGTGTATT | p.Asp372GlyfsTer91 | p.D372Gfs*91 | Q9UHF4 | protein_coding | | | TCGA-BG-A0M7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
IL20RA | SNV | Missense_Mutation | | c.871A>G | p.Ile291Val | p.I291V | Q9UHF4 | protein_coding | tolerated(0.12) | benign(0.091) | TCGA-CC-A3MC-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
IL20RA | SNV | Missense_Mutation | | c.1082N>A | p.Gly361Glu | p.G361E | Q9UHF4 | protein_coding | tolerated(0.66) | benign(0.425) | TCGA-05-4417-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IL20RA | SNV | Missense_Mutation | novel | c.348G>T | p.Trp116Cys | p.W116C | Q9UHF4 | protein_coding | deleterious(0.04) | probably_damaging(0.961) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD |